profit from every €100 of sales.
€0€100
Carl Zeiss Meditec
€33.98-2.80% today
-14.9% since Dec 16, 25
1-year low €23.421-year high €42.64
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay €21.06 for every €1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Carl Zeiss Meditec sold, what it kept, and what it did with the cash.
Sales went from €1.90 billion in 2022 to €2.23 billion in 2025, with €141 million of profit last year.
SalesProfit
Carl Zeiss Meditec handed back 39% of the cash it generated last year.
€53M
Free cash flow 2025€133M
Bought back its own shares€0
Paid as dividends€53M
Cash vs. debt€27M vs. €132M
Carl Zeiss Meditec vs. similar companies
Carl Zeiss Meditec grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| Carl Zeiss Meditec | 21.1× · Fair price | ||
 Intuitive Surgical | 55.9× · Expensive | ||
 EssilorLuxottica Société anonyme | 37.7× · Expensive | ||
 Becton, Dickinson and | 34.9× · Expensive | ||
 Medline | 46.2× · Expensive |
AI analysis
An AI analyst reads Carl Zeiss Meditec's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,903 | 2,089 | 2,066 | 2,228 | |
| 1,128 | 1,206 | 1,089 | 1,175 | |
| 397 | 348 | 194 | 223 | |
| 483 | 502 | 403 | 347 | |
| 294 | 290 | 179 | 141 | |
| 3.29 | 3.25 | 2.01 | 1.61 | |
| 59.3% | 57.7% | 52.7% | 52.8% | |
| 20.9% | 16.7% | 9.4% | 10.0% | |
| 15.4% | 13.9% | 8.7% | 6.3% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 2,823 | 3,033 | 3,393 | 3,403 |
| Cash | 8 | 11 | 20 | 27 |
| Total debt | 128 | 156 | 151 | 132 |
| Total liabilities | 793 | 860 | 1,337 | 1,276 |
| 2,015 | 2,159 | 2,042 | 2,117 | |
| 89 | 89 | 89 | 88 | |
| 13.5% | 12.9% | 8.6% | 6.9% | |
| 14.6% | 13.4% | 8.8% | 6.7% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 188 | 251 | 247 | 210 | |
| 82 | 114 | 152 | 77 | |
| 106 | 137 | 95 | 133 | |
| Dividends paid | 80 | 98 | 98 | 53 |
| – | 0 | 150 | 0 | |
| – | – | – | – |
Valuation
- 21.1×
- –
- –
- 1.1×
- 1.3×
- 22.3×
- 8.9×
- 4.5%
- 4.7%
- 1.8%
Profitability
- 52.8%
- 10.0%
- 6.3%
- –
- 6.9%
- 10.5%
- –
- –
- –
- –
Growth
- +5.4%
- −21.2%
- –
- –
- −0.7%
Financial health
- 0.3×
- 0.06
- –
- 8.3×
- 2.34
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 42%of 948
Top 47%of 871
Top 33%of 560
Bottom 29%of 868
Top 23%of 985
1.8%of the share price, paid each year
On $1,000 invested$18a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
37.2% of its profit
Room to growStretchedMore than it earns: 39.4%
News
Carl Icahn’s CVR Energy reportedly nears $4B deal to acquire Marathon refineriesSeeking Alpha · Nov 3, 2026GURU Organic Energy announces CEO succession as Carl Goyette steps down; Tyler Ricks named Executive ChairSeeking Alpha · Sep 10, 2026Carl Icahn lowers his stake in JetBlue below the reporting thresholdSeeking Alpha · Aug 21, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
57No pass
Benjamin Graham
77Pass
Philip Fisher
48No pass
Peter Lynch
27No pass
Joel Greenblatt
34No pass
Charlie Munger
49No pass
Terry Smith
42No pass
Questions about Carl Zeiss Meditec
Is Carl Zeiss Meditec a good stock to buy?
A business with weak numbers at a fair price. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Carl Zeiss Meditec AI analysis
What does Carl Zeiss Meditec do?
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. It is in Medical Instruments & Supplies, based in Jena, Germany, with 5,798 employees.
Does Carl Zeiss Meditec pay a dividend?
Yes. At today's price the dividend is 1.8% a year, about 37% of its yearly profit. In 2025 it paid out €52.5 million in dividends.
Is Carl Zeiss Meditec stock halal?
Yes. Carl Zeiss Meditec passes our halal screen: its business is permitted and its debt is 4% of its market value, under the 30% limit. How we check
Who are Carl Zeiss Meditec's competitors?
The largest listed companies in the same industry are Intuitive Surgical, EssilorLuxottica Société anonyme, Becton, Dickinson and and Medline. The peers table on this page compares their profit, growth and price with Carl Zeiss Meditec's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.